6121 Hollis Street
49 articles about Zymergen
Ginkgo Bioworks Holdings, Inc. today announced that in connection with its transaction with Bayer CropScience LP ("Bayer") on October 17, 2022, Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of Zymergen Inc. ("Zymergen") on October 19, 2022.
Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen.
In an SEC filing, Zymergen revealed it was cutting 80 more jobs and parting with Zach Serber, its co-founder and chief scientific officer.
The transaction, Ginkgo's largest acquisition to date, is expected to close by the first quarter of 2023, subject to regulatory approval and other closing conditions.
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science tools.
Zymergen Inc. (“Zymergen” or the “Company”) today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines.
Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications
Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications.
Zymergen Inc., announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octant’s next-generation platform to develop breakthrough medicines.
Biotechnology company Zymergen Inc., reported preliminary financial results for the first quarter ended March 31, 2022.
Zymergen Inc. (“Zymergen” or the “Company”), today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference held in Las Vegas, NV.
Zymergen Inc. (“Zymergen” or the “Company”) today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022.
Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the fourth quarter and full year ended December 31, 2021.
Zymergen to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on March 22nd, 2022
Zymergen Inc. announced it will report preliminary financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 22nd, 2022.
Biotechnology company Zymergen is pleased to announce early results from its work on infectious disease, discovering hundreds of potential novel hits against malaria, tuberculosis, and COVID-19 targets.
Zymergen Inc., announced the company will be participating in the upcoming 42nd Annual Cowen Virtual Healthcare Conference.
Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morgan Healthcare Conference
Biotechnology company Zymergen announced a new Automation business and updated portfolio, further refining the company’s focus on high-value solutions where its proprietary platform can provide distinct advantages.
Zymergen Inc. (“Zymergen”or the “Company”), today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference.
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
The job cuts, which affect a variety of functions and levels, are expected to slow its cash burn rate and leave the company with sufficient funds on hand to operate until mid-2023.